0001372514-23-000148.txt : 20231003
0001372514-23-000148.hdr.sgml : 20231003
20231003164726
ACCESSION NUMBER: 0001372514-23-000148
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230929
FILED AS OF DATE: 20231003
DATE AS OF CHANGE: 20231003
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Strem Brian M.
CENTRAL INDEX KEY: 0001876429
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36672
FILM NUMBER: 231304761
MAIL ADDRESS:
STREET 1: C/O EYEGATE PHARMACEUTICALS INC.
STREET 2: 271 WAVERLY OAKS RD., STE 108
CITY: WALTHAM
STATE: MA
ZIP: 02452
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: KIORA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001372514
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 332 ENCINITAS BOULEVARD
STREET 2: SUITE 102
CITY: ENCINITAS
STATE: CA
ZIP: 92024
BUSINESS PHONE: 781-788-8869
MAIL ADDRESS:
STREET 1: 332 ENCINITAS BOULEVARD
STREET 2: SUITE 102
CITY: ENCINITAS
STATE: CA
ZIP: 92024
FORMER COMPANY:
FORMER CONFORMED NAME: EYEGATE PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20060811
4
1
wk-form4_1696366025.xml
FORM 4
X0508
4
2023-09-29
0
0001372514
KIORA PHARMACEUTICALS INC
KPRX
0001876429
Strem Brian M.
C/O KIORA PHARMACEUTICALS, INC.
332 ENCINITAS BLVD., SUITE 102
ENCINITAS
CA
92024
1
1
0
0
President and CEO
0
Common Stock
2023-09-29
4
A
0
75000
0
A
103783
D
Stock Option (right to buy)
0.5677
2023-09-29
4
A
0
150000
0
A
2023-09-29
2033-09-29
Common Stock
150000
150000
D
Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan (the "Plan"). The restrictions will vest as to twenty-five percent (25%) of the shares immediately upon grant, and twenty-five percent (25%) on each of September 29, 2024, September 29, 2025 and September 29, 2026, subject to the reporting person's continuous service through each such vesting date.
The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to twenty-five percent (25%) of the shares underlying the Option upon grant on September 29, 2023, twenty-five percent (25%) on September 29, 2024 and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date.
/s/ Melissa Tosca, Attorney-in-Fact
2023-10-03